Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MTA1 short hairpin RNA-modified mesenchymal stem cells
- Development stage
- Preclinical
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, Stem Cell Therapies → Cell Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Injection
01
Overview
MTA1 short hairpin RNA-modified mesenchymal stem cells are an experimental cell-based gene therapy designed to treat triple-negative breast cancer (TNBC) by remodeling the metastatic niche. This therapeutic approach involves the stable transfection of human mesenchymal stem cells (MSCs) with short hairpin RNA (shRNA) to silence the expression of Metastasis-associated protein-1 (MTA1), a key chromatin regulator that drives the epithelial-to-mesenchymal transition (EMT). By suppressing MTA1 in the stromal compartment, these modified MSCs inhibit tumor-stroma crosstalk, reduce matrix metalloproteinase-2 (MMP-2) activity, and impair angiogenic tube formation. Preclinical studies demonstrate that these cells can significantly inhibit primary tumor growth and profoundly reduce lung and brain metastases by inducing EMT reversal in tumor cells, characterized by increased E-cadherin and decreased Vimentin and Snail expression.
- Other names
- MTA1-shRNA-modified MSCsMTA-1-shRNA-modified MSCsMTA 1-shRNA-modified MSCsMTA1-KD MSCsMTA-1-KD MSCsMTA 1-KD MSCs
02
Targets
MTA1 (Metastasis-associated protein 1)
Beyond the preview
Go deeper on MTA1 short hairpin RNA-modified mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MTA1 short hairpin RNA-modified mesenchymal stem cells.